Alcon (ALC) Proxy Filing summary

Executive summary

• Alcon has agreed to acquire STAAR Surgical for $28 per share in cash, valuing STAAR at approximately $1.5 billion in equity value, representing a 59% premium to STAAR's 90-day VWAP and a 51% premium to the closing price on August 4, 2025.

• The acquisition is expected to be accretive to Alcon's earnings in year two and will expand Alcon's offerings in surgical vision correction, particularly for moderate to high myopia.

• The transaction is anticipated to close in six to twelve months, subject to regulatory and shareholder approval, and is not subject to a financing condition.

• Both companies' boards have unanimously approved the transaction, and the deal is positioned as the best path forward for STAAR shareholders.

Voting matters and shareholder proposals

• STAAR will announce a special stockholder meeting to obtain approval for the proposed merger.

• A definitive proxy statement and other relevant documents will be filed with the SEC for shareholder review.

Board of directors and corporate governance

• The boards of both Alcon and STAAR have unanimously approved the merger agreement.

• Financial and legal advisors have been engaged by both companies to support the transaction.